Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Syngene lines up $200...

    Syngene lines up $200 million capex to boost manufacturing

    Written by savita thakur thakur Published On 2016-07-24T15:43:30+05:30  |  Updated On 24 July 2016 3:43 PM IST
    Syngene lines up $200 million capex to boost manufacturing

    New Delhi : Biocon's contract research arm Syngene International has lined up $200 million (around Rs 1,342 crore) capex to bolster its manufacturing capabilities over the next three years.


    The company plans to invest $100 million (around Rs 665.27 crore) in a greenfield facility at Mangalore, the first phase of which would be operationalised by financial year 2018-19.


    Besides, it has also earmarked another $100 million to create additional infrastructure at its existing facility at Bangalore.


    "We have acquired a site at Mangalore. We plan to come up with a manufacturing base there in line with long term strategy of the company. The unit, when functional, would support our existing Bangalore complex," Syngene International Ltd CEO Jonathan Hunt told reporters during a conference call.


    The first phase of the facility is expected to be completed by 2018-19, he added.


    Syngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology and toxicology.


    The company had reported a 28.32 per cent rise in standalone net profit to Rs 59.8 crore for the quarter ended on June 30, 2016.


    When asked about the product pipeline, Hunt said the company has a "healthy high single digit" product pipeline which is in various stages of development."


    In 2015-16, Syngene serviced 256 clients including 8 of the top 10 global pharma companies.


    Shares of Syngene International were trading 0.65 per cent up at Rs 430.55 apiece on BSE.

    Bioconglobal pharma industryhealthy high single digitInvestmentJonathan HuntSyngene International
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok